Arbutus Biopharma (ABUS) Common Equity (2010 - 2026)

Arbutus Biopharma has disclosed Common Equity across 17 years of filings, most recently posting $260.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $260.2 million, up 228.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $260.2 million (up 228.68% YoY), and the FY2025 annual result was $76.6 million, down 21.35% from the prior year.
• Common Equity came in at $260.2 million for Q1 2026 at Arbutus Biopharma, up from $76.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $260.2 million in Q1 2026 to a low of $76.6 million in Q4 2025.
• The 5-year median for Common Equity is $119.3 million (2023), against an average of $124.9 million.
• Across the five-year window, Common Equity tumbled 32.24% in 2025 and soared 228.68% in 2026, its largest moves.
• Arbutus Biopharma's Common Equity stood at $136.9 million in 2022, then retreated by 22.53% to $106.0 million in 2023, then fell by 8.16% to $97.4 million in 2024, then slipped by 21.35% to $76.6 million in 2025, then soared by 239.76% to $260.2 million in 2026.
• The last three Common Equity figures came in at $260.2 million (Q1 2026), $76.6 million (Q4 2025), and $77.4 million (Q3 2025), per Business Quant data.